NBAT1/CASC15-003/USP36 control MYCN expression and its downstream pathway genes in neuroblastoma

Prasanna Kumar Juvvuna; Tanmoy Mondal; Mirco Di Marco; Subazini Thankaswamy Kosalai; Meena Kanduri; Chandrasekhar Kanduri

doi:10.1093/noajnl/vdab056

NBAT1/CASC15-003/USP36 control MYCN expression and its downstream pathway genes in neuroblastoma

Neurooncol Adv. 2021 Apr 9;3(1):vdab056. doi: 10.1093/noajnl/vdab056. eCollection 2021 Jan-Dec.

Authors

Prasanna Kumar Juvvuna¹, Tanmoy Mondal², Mirco Di Marco¹, Subazini Thankaswamy Kosalai¹, Meena Kanduri³, Chandrasekhar Kanduri¹

Affiliations

¹ Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
² Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
³ Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.

Abstract

Background: MYCN has been an attractive therapeutic target in neuroblastoma considering the widespread amplification of the MYCN locus in neuroblastoma, and its established role in neuroblastoma development and progression. Thus, understanding neuroblastoma-specific control of MYCN expression at the transcriptional and post-transcriptional level would lead to identification of novel MYCN-dependent oncogenic pathways and potential therapeutic strategies.

Methods: By performing loss- and gain-of-function experiments of the neuroblastoma hotspot locus 6p22.3 derived lncRNAs CASC15-003 and NBAT1, together with coimmunoprecipitation and immunoblotting of MYCN, we have shown that both lncRNAs post-translationally control the expression of MYCN through regulating a deubiquitinase enzyme USP36. USP36 oncogenic properties were investigated using cancer cell lines and in vivo models. RNA-seq analysis of loss-of-function experiments of CASC15-003/NBAT1/MYCN/USP36 and JQ1-treated neuroblastoma cells uncovered MYCN-dependent oncogenic pathways.

Results: We show that NBAT1/CASC15-003 control the stability of MYCN protein through their common interacting protein partner USP36. USP36 harbors oncogenic properties and its higher expression in neuroblastoma patients correlates with poor prognosis, and its downregulation significantly reduces tumor growth in neuroblastoma cell lines and xenograft models. Unbiased integration of RNA-seq data from CASC15-003, NBAT1, USP36, and MYCN knockdowns and neuroblastoma cells treated with MYCN inhibitor JQ1, identified genes that are jointly regulated by the NBAT1/CASC15-003/USP36/MYCN pathway. Functional experiments on one of the target genes, COL18A1, revealed its role in the NBAT1/CASC15-003-dependent cell adhesion feature in neuroblastoma cells.

Conclusion: Our data show post-translational regulation of MYCN by NBAT1/CASC15-003/USP36, which represents a new regulatory layer in the complex multilayered gene regulatory network that controls MYCN expression.

Keywords: CASC15; COL18A1; MYCN; NBAT1; USP36; long noncoding RNA; neuroblastoma.